Insights into pituitary tumorigenesis: from Sanger sequencing to next-generation sequencing and beyond

References

• Rogers A, Karavitaki N, Wass JA. Diagnosis and management of prolactinomas and non-functioning pituitary adenomas. BMJ. 2014;349:g5390.
   PubMedGoogle Scholar
• Levy A. Molecular and trophic mechanisms of tumorigenesis. Endocrinol Metab Clin North Am. 2008;37(1):23.
   PubMed Web of Science ®Google Scholar
• Snyder PJ. Gonadotroph cell adenomas of the pituitary. Endocr Rev. 1985;6(4):552–563.
   PubMed Web of Science ®Google Scholar
• Mete O, Lopes MB. Overview of the 2017 WHO classification of pituitary tumors. Endocr Pathol. 2017;28:228–243.
   Web of Science ®Google Scholar
• Bevan JS. Pituitary incidentaloma. Clin Med (Lond). 2013;13(3):296–298.
   PubMed Web of Science ®Google Scholar
• Vasilev V, Rostomyan L, Daly AF, et al. MANAGEMENT OF ENDOCRINE DISEASE: pituitary ‘incidentaloma’: neuroradiological assessment and differential diagnosis. Eur J Endocrinol. 2016;175(4):R171–184.
   PubMed Web of Science ®Google Scholar
• Scully KM, Rosenfeld MG. Pituitary development: regulatory codes in mammalian organogenesis. Science. 2002;295(5563):2231–2235.
   PubMed Web of Science ®Google Scholar
• Zafar M, Ezzat S, Ramyar L, et al. Cell-specific expression of estrogen receptor in the human pituitary and its adenomas. J Clin Endocrinol Metab. 1995;80(12):3621–3627.
   PubMed Web of Science ®Google Scholar
• Asa SL, Casar-Borota O, Chanson P, et al. From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. (Ed.^(Eds)). 2017;24(4):C5–C8.
   Google Scholar
• Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas: a systematic review. Cancer. 2004;101(3):613–619.
   PubMed Web of Science ®Google Scholar
• van Dijk EL, Auger H, Jaszczyszyn Y, et al. Ten years of next-generation sequencing technology. Trends Genet. 2014;30(9):418–426.
   PubMed Web of Science ®Google Scholar
• Turcatti G, Romieu A, Fedurco M, et al. A new class of cleavable fluorescent nucleotides: synthesis and optimization as reversible terminators for DNA sequencing by synthesis. Nucleic Acids Res. 2008;36(4):e25.
   PubMed Web of Science ®Google Scholar
• Luo C, Tsementzi D, Kyrpides N, et al. Direct comparisons of Illumina vs. Roche 454 sequencing technologies on the same microbial community DNA sample. Plos One. 2012;7(2):e30087–e30087.
   PubMed Web of Science ®Google Scholar
• Quail MA, Smith M, Coupland P, et al. A tale of three next generation sequencing platforms: comparison of ion torrent, pacific biosciences and illumina MiSeq sequencers. BMC Genomics. 2012;13:341.
   PubMed Web of Science ®Google Scholar
• McKernan KJ, Peckham HE, Costa GL, et al. Sequence and structural variation in a human genome uncovered by short-read, massively parallel ligation sequencing using two-base encoding. Genome Res. 2009;19(9):1527–1541.
   PubMed Web of Science ®Google Scholar
• Macevicz SC. DNA sequencing by parallel oligonucleotide extensions. (Ed.^(Eds)). 1998.
   Google Scholar
• Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990–3011.
   PubMed Web of Science ®Google Scholar
• Alrezk R, Hannah-Shmouni F, Stratakis CA. MEN4 and CDKN1B mutations: the latest of the MEN syndromes. Endocr Relat Cancer. 2017;24(10):T195–T208.
   PubMed Web of Science ®Google Scholar
• Agarwal SK, Mateo CM, Marx SJ. Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J Clin Endocrinol Metab. 2009;94(5):1826–1834.
   PubMed Web of Science ®Google Scholar
• Georgitsi M, Raitila A, Karhu A, et al. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J Clin Endocrinol Metab. 2007;92(8):3321–3325.
   PubMed Web of Science ®Google Scholar
• Pellegata NS, Quintanilla-Martinez L, Siggelkow H, et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci U S A. 2006;103(42):15558–15563.
   PubMed Web of Science ®Google Scholar
• Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol. 2014;386(1–2):2–15.
   PubMed Web of Science ®Google Scholar
• de Laat JM, van der Luijt RB, Pieterman CR, et al. MEN1 redefined, a clinical comparison of mutation-positive and mutation-negative patients. BMC Med. 2016;14(1):182.
   PubMedGoogle Scholar
• Pellegata NS. MENX and MEN4. Clinics (Sao Paulo). 2012;67(Suppl 1):13–18.
   PubMedGoogle Scholar
• Larsson C, Skogseid B, Oberg K, et al. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature. 1988;332(6159):85–87.
   PubMed Web of Science ®Google Scholar
• Bystrom C, Larsson C, Blomberg C, et al. Localization of the MEN1 gene to a small region within chromosome 11q13 by deletion mapping in tumors. Proc Natl Acad Sci U S A. 1990;87(5):1968–1972.
   PubMed Web of Science ®Google Scholar
• Agarwal SK, Guru SC, Heppner C, et al. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell. 1999;96(1):143–152.
   PubMed Web of Science ®Google Scholar
• Balogh K, Patócs A, Hunyady L, et al. Menin dynamics and functional insight: take your partners. Mol Cell Endocrinol. 2010;326(1–2):80–84.
   PubMed Web of Science ®Google Scholar
• Borsari S, Pardi E, Pellegata NS, et al. Loss of p27 expression is associated with MEN1 gene mutations in sporadic parathyroid adenomas. Endocrine. 2017;55(2):386–397.
   PubMed Web of Science ®Google Scholar
• Hengst L, Dulic V, Slingerland JM, et al. A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc Natl Acad Sci U S A. 1994;91(12):5291–5295.
   PubMed Web of Science ®Google Scholar
• Flanagan DE, Armitage M, Clein GP, et al. Prolactinoma presenting in identical twins with multiple endocrine neoplasia type 1. Clin Endocrinol (Oxf). 1996;45(1):117–120.
   PubMed Web of Science ®Google Scholar
• Bassett JH, Forbes SA, Pannett AA, et al. Characterization of mutations in patients with multiple endocrine neoplasia type 1. Am J Hum Genet. 1998;62(2):232–244.
   PubMed Web of Science ®Google Scholar
• Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat. 2008;29(1):22–32.
   PubMed Web of Science ®Google Scholar
• Carney JA, Gordon H, Carpenter PC, et al. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore). 1985;64(4):270–283.
   PubMed Web of Science ®Google Scholar
• Correa R, Salpea P, Stratakis CA. Carney complex: an update. Eur J Endocrinol. 2015;173(4):M85–97.
   PubMed Web of Science ®Google Scholar
• Hernandez-Ramirez LC, Tatsi C, Lodish MB, et al. Corticotropinoma as a component of Carney complex. J Endocr Soc. 2017;1(7):918–925.
   PubMed Web of Science ®Google Scholar
• Kiefer FW, Winhofer Y, Iacovazzo D, et al. PRKAR1A mutation causing pituitary-dependent Cushing disease in a patient with Carney complex. Eur J Endocrinol. 2017;177(2):K7–K12.
   PubMed Web of Science ®Google Scholar
• Stratakis CA, Jenkins RB, Pras E, et al. Cytogenetic and microsatellite alterations in tumors from patients with the syndrome of myxomas, spotty skin pigmentation, and endocrine overactivity (Carney complex). J Clin Endocrinol Metab. 1996;81(10):3607–3614.
   PubMed Web of Science ®Google Scholar
• Casey M, Mah C, Merliss AD, et al. Identification of a novel genetic locus for familial cardiac myxomas and Carney complex. Circulation. 1998;98(23):2560–2566.
   PubMed Web of Science ®Google Scholar
• Cazabat L, Ragazzon B, Groussin L, et al. PRKAR1A mutations in primary pigmented nodular adrenocortical disease. Pituitary. 2006;9(3):211–219.
   PubMedGoogle Scholar
• Kirschner LS. PRKAR1A and the evolution of pituitary tumors. Mol Cell Endocrinol. 2010;326(1–2):3–7.
   PubMed Web of Science ®Google Scholar
• Robinson-White A, Hundley TR, Shiferaw M, et al. Protein kinase-A activity in PRKAR1A-mutant cells, and regulation of mitogen-activated protein kinases ERK1/2. Hum Mol Genet. 2003;12(13):1475–1484.
   PubMed Web of Science ®Google Scholar
• Chen AE, Ginty DD, Fan CM. Protein kinase A signalling via CREB controls myogenesis induced by Wnt proteins. Nature. 2005;433(7023):317–322.
   PubMed Web of Science ®Google Scholar
• Salpea P, Stratakis CA. Carney complex and McCune Albright syndrome: an overview of clinical manifestations and human molecular genetics. Mol Cell Endocrinol. 2014;386(1–2):85–91.
   PubMed Web of Science ®Google Scholar
• Kirschner LS, Carney JA, Pack SD, et al. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet. 2000;26(1):89–92.
   PubMed Web of Science ®Google Scholar
• Gaujoux S, Chanson P, Bertherat J, et al. Hepato-pancreato-biliary lesions are present in both Carney complex and McCune Albright syndrome: comments on P. Salpea and C. Stratakis. Mol Cell Endocrinol. 2014;382(1):344–345.
   PubMed Web of Science ®Google Scholar
• Shenker A, Weinstein LS, Moran A, et al. Severe endocrine and nonendocrine manifestations of the McCune-Albright syndrome associated with activating mutations of stimulatory G protein GS. J Pediatr. 1993;123(4):509–518.
   PubMed Web of Science ®Google Scholar
• Lala R, Matarazzo P, Andreo M, et al. Impact of endocrine hyperfunction and phosphate wasting on bone in McCune-Albright syndrome. J Pediatr Endocrinol Metab. 2002;15(Suppl 3):913–920.
   PubMedGoogle Scholar
• Weinstein LS, Shenker A, Gejman PV, et al. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med. 1991;325(24):1688–1695.
   PubMed Web of Science ®Google Scholar
• Brown RJ, Kelly MH, Collins MT. Cushing syndrome in the McCune-Albright syndrome. J Clin Endocrinol Metab. 2010;95(4):1508–1515.
   PubMed Web of Science ®Google Scholar
• Slade I, Bacchelli C, Davies H, et al. DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome. J Med Genet. 2011;48(4):273–278.
   PubMed Web of Science ®Google Scholar
• Robertson JC, Jorcyk CL, Oxford JT. DICER1 syndrome: DICER1 mutations in rare cancers. Cancers (Basel). 2018;10(5):143.
   PubMed Web of Science ®Google Scholar
• de Kock L, Sabbaghian N, Plourde F, et al. Pituitary blastoma: a pathognomonic feature of germ-line DICER1 mutations. Acta Neuropathol. 2014;128(1):111–122.
   PubMed Web of Science ®Google Scholar
• Chiosea S, Acquafondata M, Luo J, et al. DICER1 and PRKRA in colon adenocarcinoma. Biomark Insights. 2008;3:253–258.
   PubMedGoogle Scholar
• Sahakitrungruang T, Srichomthong C, Pornkunwilai S, et al. Germline and somatic DICER1 mutations in a pituitary blastoma causing infantile-onset Cushing’s disease. J Clin Endocrinol Metab. 2014;99(8):E1487–1492.
   PubMed Web of Science ®Google Scholar
• Scheithauer BW, Kovacs K, Horvath E, et al. Pituitary blastoma. Acta Neuropathol. 2008;116(6):657–666.
   PubMed Web of Science ®Google Scholar
• Scheithauer BW, Horvath E, Abel TW, et al. Pituitary blastoma: a unique embryonal tumor. Pituitary. 2012;15(3):365–373.
   PubMed Web of Science ®Google Scholar
• Xekouki P, Stratakis CA. Succinate dehydrogenase (SDHx) mutations in pituitary tumors: could this be a new role for mitochondrial complex II and/or Krebs cycle defects? Endocr Relat Cancer. 2012;19(6):C33–40.
   PubMed Web of Science ®Google Scholar
• O’Toole SM, Denes J, Robledo M, et al. 15 YEARS OF PARAGANGLIOMA: the association of pituitary adenomas and phaeochromocytomas or paragangliomas. Endocr Relat Cancer. 2015;22(4):T105–122.
   PubMed Web of Science ®Google Scholar
• Denes J, Swords F, Rattenberry E, et al. Heterogeneous genetic background of the association of pheochromocytoma/paraganglioma and pituitary adenoma: results from a large patient cohort. J Clin Endocrinol Metab. 2015;100(3):E531–541.
   PubMed Web of Science ®Google Scholar
• Vierimaa O, Georgitsi M, Lehtonen R, et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science. 2006;312(5777):1228–1230.
   PubMed Web of Science ®Google Scholar
• Tichomirowa MA, Barlier A, Daly AF, et al. High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur J Endocrinol/Eur Fed Endocr Soc. 2011;165(4):509–515.
   PubMed Web of Science ®Google Scholar
• Cazabat L, Bouligand J, Salenave S, et al. Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients. J Clin Endocrinol Metab. 2012;97(4):E663–E670.
   PubMed Web of Science ®Google Scholar
• Cai F, Zhang YD, Zhao X, et al. Screening for AIP gene mutations in a Han Chinese pituitary adenoma cohort followed by LOH analysis. Eur J Endocrinol. 2013;169(6):867–884.
   PubMed Web of Science ®Google Scholar
• Iacovazzo D, Caswell R, Bunce B, et al. Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study. Acta Neuropathol Commun. 2016;4(1):56.
   PubMedGoogle Scholar
• Beckers A, Aaltonen LA, Daly AF, et al. Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocr Rev. 2013;34(2):239–277.
   PubMed Web of Science ®Google Scholar
• Fan Y, Boivin GP, Knudsen ES, et al. The aryl hydrocarbon receptor functions as a tumor suppressor of liver carcinogenesis. Cancer Res. 2010;70(1):212–220.
   PubMed Web of Science ®Google Scholar
• Elizondo G, Fernandez-Salguero P, Sheikh MS, et al. Altered cell cycle control at the G(2)/M phases in aryl hydrocarbon receptor-null embryo fibroblast. Mol Pharmacol. 2000;57(5):1056–1063.
   PubMed Web of Science ®Google Scholar
• Bolger GB, Peden AH, Steele MR, et al. Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2. J Biol Chem. 2003;278(35):33351–33363.
   PubMed Web of Science ®Google Scholar
• Formosa R, Xuereb-Anastasi A, Vassallo J. Aip regulates cAMP signalling and GH secretion in GH3 cells. Endocr Relat Cancer. 2013;20(4):495–505.
   PubMed Web of Science ®Google Scholar
• Kang BH, Altieri DC. Regulation of survivin stability by the aryl hydrocarbon receptor-interacting protein. J Biol Chem. 2006;281(34):24721–24727.
   PubMed Web of Science ®Google Scholar
• Daly AF, Tichomirowa MA, Petrossians P, et al. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab. 2010;95(11):E373–383.
   PubMed Web of Science ®Google Scholar
• Daly AF, Vanbellinghen J-F, Khoo SK, et al. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab. 2007;92(5):1891–1896.
   PubMed Web of Science ®Google Scholar
• Cazabat L, Libè R, Perlemoine K, et al. Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. Eur J Endocrinol/Eur Fed Endocr Soc. 2007;157(1):1–8.
   PubMed Web of Science ®Google Scholar
• Matsumoto R, Izawa M, Fukuoka H, et al. Genetic and clinical characteristics of Japanese patients with sporadic somatotropinoma. Endocr J. 2016;63(11):953–963.
   PubMed Web of Science ®Google Scholar
• Hernández-Ramírez LC, Gabrovska P, Dénes J, et al. Landscape of familial isolated and young-onset pituitary adenomas: prospective diagnosis in AIP mutation carriers. J Clin Endocrinol Metab. 2015;100(9):E1242–E1254.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Peng C, Song J, et al. Germline mutations in CDH23, encoding cadherin-related 23, are associated with both familial and sporadic pituitary adenomas. Am J Hum Genet. 2017;100(5):817–823.
   PubMed Web of Science ®Google Scholar
• Tepass U, Truong K, Godt D, et al. Cadherins in embryonic and neural morphogenesis. Nat Rev Mol Cell Biol. 2000;1(2):91–100.
   PubMed Web of Science ®Google Scholar
• Qian ZR, Sano T, Yoshimoto K, et al. Tumor-specific downregulation and methylation of the CDH13 (H-cadherin) and CDH1 (E-cadherin) genes correlate with aggressiveness of human pituitary adenomas. Mod Pathol. 2007;20(12):1269–1277.
   PubMed Web of Science ®Google Scholar
• Ongaratti BR, Haag T, D’Avila MF, et al. Gene and protein expression of E-cadherin and NCAM markers in non-functioning pituitary adenomas. Ann Diagn Pathol. 2019;38:59–61.
   PubMed Web of Science ®Google Scholar
• Zhou K, Jin H, Luo Y. Expression and significance of E-cadherin and beta-catenins in pituitary adenoma. Int J Surg Pathol. 2013;21(4):363–367.
   PubMed Web of Science ®Google Scholar
• Fougner SL, Lekva T, Borota OC, et al. The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response. J Clin Endocrinol Metab. 2010;95(5):2334–2342.
   PubMed Web of Science ®Google Scholar
• Sannigrahi MK, Srinivas CS, Deokate N, et al. The strong propensity of Cadherin-23 for aggregation inhibits cell migration. Mol Oncol. 2019;13(5):1092–1109.
   PubMed Web of Science ®Google Scholar
• Dworakowska D, Grossman AB. The molecular pathogenesis of corticotroph tumours. Eur J Clin Invest. 2012;42(6):665–676.
   PubMed Web of Science ®Google Scholar
• Peverelli E, Giardino E, Treppiedi D, et al. Dopamine receptor type 2 (DRD2) and somatostatin receptor type 2 (SSTR2) agonists are effective in inhibiting proliferation of progenitor/stem-like cells isolated from nonfunctioning pituitary tumors. Int J Cancer. 2017;140(8):1870–1880.
   PubMed Web of Science ®Google Scholar
• Beaulieu JM, Espinoza S, Gainetdinov RR. Dopamine receptors - IUPHAR Review 13. Br J Pharmacol. 2015;172(1):1–23.
   PubMed Web of Science ®Google Scholar
• Molitch ME. Management of medically refractory prolactinoma. J Neurooncol. 2014;117(3):421–428.
   PubMed Web of Science ®Google Scholar
• Gillam MP, Molitch ME, Lombardi G, et al. Advances in the treatment of prolactinomas. Endocr Rev. 2006;27(5):485–534.
   PubMed Web of Science ®Google Scholar
• International Human Genome Sequencing C. Finishing the euchromatic sequence of the human genome. Nature. 2004;431(7011):931–945.
   PubMed Web of Science ®Google Scholar
• Oh MC, Aghi MK. Dopamine agonist-resistant prolactinomas. J Neurosurg. 2011;114(5):1369–1379.
   PubMed Web of Science ®Google Scholar
• Vroonen L, Jaffrain-Rea ML, Petrossians P, et al. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur J Endocrinol. 2012;167(5):651–662.
   PubMed Web of Science ®Google Scholar
• Wang F, Gao H, Li C, et al. Low levels of PRB3 mRNA are associated with dopamine-agonist resistance and tumor recurrence in prolactinomas. J Neurooncol. 2014;83(1):83-88.
   Google Scholar
• Schuff KG, Hentges ST, Kelly MA, et al. Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms. J Clin Invest. 2002;110(7):973–981.
   PubMed Web of Science ®Google Scholar
• Bernard V, Bouilly J, Beau I, et al. Germline prolactin receptor mutation is not a major cause of sporadic prolactinoma in humans. Neuroendocrinology. 2016;103(6):738–745.
   PubMed Web of Science ®Google Scholar
• De Sousa SMC, Wang PPS, Santoreneos S, et al. The genomic landscape of sporadic prolactinomas. Endocr Pathol. 2019. Available from: https://link.springer.com/journal/12022/onlineFirst
   PubMedGoogle Scholar
• Kauppinen-Makelin R, Sane T, Reunanen A, et al. A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab. 2005;90(7):4081–4086.
   PubMed Web of Science ®Google Scholar
• Dal J, Feldt-Rasmussen U, Andersen M, et al. Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study. Eur J Endocrinol. 2016;175(3):181–190.
   PubMed Web of Science ®Google Scholar
• Ritvonen E, Löyttyniemi E, Jaatinen P, et al. Mortality in acromegaly: a 20-year follow-up study. Endocr Relat Cancer. 2016;23(6):469–480.
   PubMed Web of Science ®Google Scholar
• Dekkers OM, Biermasz NR, Pereira AM, et al. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2008;93(1):61–67.
   PubMed Web of Science ®Google Scholar
• Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol. 2008;159(2):89–95.
   PubMed Web of Science ®Google Scholar
• Arosio M, Reimondo G, Malchiodi E, et al. Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol. 2012;167(2):189–198.
   PubMed Web of Science ®Google Scholar
• Esposito D, Ragnarsson O, Granfeldt D, et al. Decreasing mortality and changes in treatment patterns in patients with acromegaly from a nationwide study. Eur J Endocrinol. 2018;178(5):459–469.
   PubMed Web of Science ®Google Scholar
• Bolfi F, Neves AF, Boguszewski CL, et al. Mortality in Acromegaly decreased in the last decade: a systematic review and meta-analysis. Eur J Endocrinol. 2018;179:59–71.
   Web of Science ®Google Scholar
• Vallar L, Spada A, Giannattasio G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature. 1987;330(6148):566–568.
   PubMed Web of Science ®Google Scholar
• Välimäki N, Demir H, Pitkänen E, et al. Whole-genome sequencing of growth hormone (GH)-secreting pituitary adenomas. J Clin Endocrinol Metab. 2015;100(10):3918–3927.
   PubMed Web of Science ®Google Scholar
• Landis CA, Masters SB, Spada A, et al. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature. 1989;340(6236):692–696.
   PubMed Web of Science ®Google Scholar
• Billestrup N, Swanson LW, Vale W. Growth hormone-releasing factor stimulates proliferation of somatotrophs in vitro. Proc Natl Acad Sci U S A. 1986;83(18):6854–6857.
   PubMed Web of Science ®Google Scholar
• Hayward BE, Barlier A, Korbonits M, et al. Imprinting of the G(s)alpha gene GNAS1 in the pathogenesis of acromegaly. J Clin Invest. 2001;107(6):R31–R36.
   PubMed Web of Science ®Google Scholar
• Mantovani G, Lania AG, Spada A. GNAS imprinting and pituitary tumors. Mol Cell Endocrinol. 2010;326(1–2):15–18.
   PubMed Web of Science ®Google Scholar
• Freda PU, Chung WK, Matsuoka N, et al. Analysis of GNAS mutations in 60 growth hormone secreting pituitary tumors: correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-I criteria for remission. Pituitary. 2007;10(3):275–282.
   PubMed Web of Science ®Google Scholar
• Shi Y, Tang D, Deng J, et al. Detection of gsp oncogene in growth hormone-secreting pituitary adenomas and the study of clinical characteristics of acromegalic patients with gsp-positive pituitary tumors. Chin Med J (Engl). 1998;111(10):891–894.
   PubMed Web of Science ®Google Scholar
• Vortmeyer AO, Gläsker S, Mehta GU, et al. Somatic GNAS mutation causes widespread and diffuse pituitary disease in acromegalic patients with McCune-Albright syndrome. J Clin Endocrinol Metab. 2012;97(7):2404–2413.
   PubMed Web of Science ®Google Scholar
• Ronchi CL, Peverelli E, Herterich S, et al. Landscape of somatic mutations in sporadic GH-secreting pituitary adenomas. Eur J Endocrinol/Eur Fed Endocr Soc. 2016;174(3):363–372.
   PubMed Web of Science ®Google Scholar
• Canny BJ, Rawlings SR, Leong DA. Pituitary adenylate cyclase-activating polypeptide specifically increases cytosolic calcium ion concentration in rat gonadotropes and somatotropes. Endocrinology. 1992;130(1):211–215.
   PubMed Web of Science ®Google Scholar
• Chen ZP, Kratzmeier M, Levy A, et al. Evidence for a role of pituitary ATP receptors in the regulation of pituitary function. Proc Natl Acad Sci U S A. 1995;92(11):5219–5223.
   PubMed Web of Science ®Google Scholar
• Lindholm J, Juul S, Jorgensen JO, et al. Incidence and late prognosis of Cushing’s syndrome: a population-based study. J Clin Endocrinol Metab. 2001;86(1):117–123.
   PubMed Web of Science ®Google Scholar
• Clayton RN. Mortality in Cushing’s disease. Neuroendocrinology. 2010;92(Suppl 1):71–76.
   PubMedGoogle Scholar
• Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889–1916.
   PubMed Web of Science ®Google Scholar
• Yaneva M, Kalinov K, Zacharieva S. Mortality in Cushing’s syndrome: data from 386 patients from a single tertiary referral center. Eur J Endocrinol. 2013;169(5):621–627.
   PubMed Web of Science ®Google Scholar
• Reincke M, Sbiera S, Hayakawa A, et al. Mutations in the deubiquitinase gene USP8 cause Cushing’s disease. Nat Genet. 2015;47(1):31–38.
   PubMed Web of Science ®Google Scholar
• Ma Z-Y, Song Z-J, Chen J-H, et al. Recurrent gain-of-function USP8 mutations in Cushing’s disease. Cell Res. 2015;25(3):306–317.
   PubMed Web of Science ®Google Scholar
• Perez-Rivas LG, Theodoropoulou M, Ferraù F, et al. The gene of the ubiquitin-specific protease 8 is frequently mutated in adenomas causing Cushing’s disease. J Clin Endocrinol Metab. 2015;100(7):E997–E1004.
   PubMed Web of Science ®Google Scholar
• Hayashi K, Inoshita N, Kawaguchi K, et al. The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing’s disease. Eur J Endocrinol. 2016;174(2):213–226.
   PubMed Web of Science ®Google Scholar
• Ballmann C, Thiel A, Korah HE, et al. USP8 mutations in pituitary cushing adenomas-targeted analysis by next-generation sequencing. J Endocr Soc. 2018;2(3):266–278.
   PubMed Web of Science ®Google Scholar
• Fukuoka H, Cooper O, Ben-Shlomo A, et al. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Invest. 2011;121(12):4712–4721.
   PubMed Web of Science ®Google Scholar
• Faucz FR, Tirosh A, Tatsi C, et al. Somatic USP8 gene mutations are a common cause of pediatric cushing disease. J Clin Endocrinol Metab. 2017;102(8):2836–2843.
   PubMed Web of Science ®Google Scholar
• Jian -F-F, Li Y-F, Chen Y-F, et al. Inhibition of ubiquitin-specific peptidase 8 suppresses adrenocorticotropic hormone production and tumorous corticotroph cell growth in AtT20 cells. Chin Med J (Engl). 2016;129(17):2102–2108.
   PubMed Web of Science ®Google Scholar
• Hernandez-Ramirez LC, Gam R, Valdes N, et al. Loss-of-function mutations in the CABLES1 gene are a novel cause of Cushing’s disease. Endocr Relat Cancer. 2017;24(8):379–392.
   PubMed Web of Science ®Google Scholar
• Matsuoka M, Matsuura Y, Semba K, et al. Molecular cloning of a cyclin-like protein associated with cyclin-dependent kinase 3 (cdk 3) in vivo. Biochem Biophys Res Commun. 2000;273(2):442–447.
   PubMed Web of Science ®Google Scholar
• Wu CL, Kirley SD, Xiao H, et al. Cables enhances cdk2 tyrosine 15 phosphorylation by Wee1, inhibits cell growth, and is lost in many human colon and squamous cancers. Cancer Res. 2001;61(19):7325–7332.
   PubMed Web of Science ®Google Scholar
• Tsuji K, Mizumoto K, Yamochi T, et al. Differential effect of ik3-1/cables on p53- and p73-induced cell death. J Biol Chem. 2002;277(4):2951–2957.
   PubMed Web of Science ®Google Scholar
• Zukerberg LR, Patrick GN, Nikolic M, et al. Cables links Cdk5 and c-Abl and facilitates Cdk5 tyrosine phosphorylation, kinase upregulation, and neurite outgrowth. Neuron. 2000;26(3):633–646.
   PubMed Web of Science ®Google Scholar
• Roussel-Gervais A, Couture C, Langlais D, et al. The cables1 gene in glucocorticoid regulation of pituitary corticotrope growth and cushing disease. J Clin Endocrinol Metab. 2016;101(2):513–522.
   PubMed Web of Science ®Google Scholar
• Beck-Peccoz P, Persani L, Mannavola D, et al. Pituitary tumours: TSH-secreting adenomas. Best Pract Res Clin Endocrinol Metab. 2009;23(5):597–606.
   PubMed Web of Science ®Google Scholar
• Ónnestam L, Berinder K, Burman P, et al. National incidence and prevalence of TSH-secreting pituitary adenomas in Sweden. J Clin Endocrinol Metab. 2013;98(2):626–635.
   PubMed Web of Science ®Google Scholar
• Asa SL, Puy LA, Lew AM, et al. Cell type-specific expression of the pituitary transcription activator pit-1 in the human pituitary and pituitary adenomas. J Clin Endocrinol Metab. 1993;77(5):1275–1280.
   PubMed Web of Science ®Google Scholar
• Sanno N, Teramoto A, Osamura RY. Thyrotropin-secreting pituitary adenomas. Clinical and biological heterogeneity and current treatment. J Neurooncol. 2001;54(2):179–186.
   PubMed Web of Science ®Google Scholar
• Orme SM, Lamb JT, Nelson M, et al. Shrinkage of thyrotrophin secreting pituitary adenoma treated with octreotide. Postgrad Med J. 1991;67(787):466–468.
   PubMed Web of Science ®Google Scholar
• Gatto F, Barbieri F, Castelletti L, et al. In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5. Pituitary. 2011;14(2):141–147.
   PubMed Web of Science ®Google Scholar
• Horiguchi K, Yamada M, Umezawa R, et al. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment. Endocr J. 2007;54(3):371–378.
   PubMed Web of Science ®Google Scholar
• Chanson P, Weintraub BD, Harris AG. Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients. Ann Intern Med. 1993;119(3):236–240.
   PubMed Web of Science ®Google Scholar
• Yoshihara A, Isozaki O, Hizuka N, et al. Expression of type 5 somatostatin receptor in TSH-secreting pituitary adenomas: a possible marker for predicting long-term response to octreotide therapy. Endocr J. 2007;54(1):133–138.
   PubMed Web of Science ®Google Scholar
• Sharif N, Gendron L, Wowchuk J, et al. Coexpression of somatostatin receptor subtype 5 affects internalization and trafficking of somatostatin receptor subtype 2. Endocrinology. 2007;148(5):2095–2105.
   PubMed Web of Science ®Google Scholar
• Fliers E, van Furth WR, Bisschop PH. Cure of a thyrotrophin (TSH)-secreting pituitary adenoma by medical therapy. Clin Endocrinol (Oxf). 2012;77(5):788–790.
   PubMed Web of Science ®Google Scholar
• Sumiyoshi Y, Inoue Y, Akiyama M. Immunohistochemical investigation of proliferating cell nuclear antigen in bladder cancer. Nihon Hinyokika Gakkai Zasshi. 1993;84(9):1643–1648.
   PubMedGoogle Scholar
• Dong Q, Brucker-Davis F, Weintraub BD, et al. Screening of candidate oncogenes in human thyrotroph tumors: absence of activating mutations of the G alpha q, G alpha 11, G alpha s, or thyrotropin-releasing hormone receptor genes. J Clin Endocrinol Metab. 1996;81(3):1134–1140.
   PubMed Web of Science ®Google Scholar
• Gittoes NJ, McCabe CJ, Verhaeg J, et al. An abnormality of thyroid hormone receptor expression may explain abnormal thyrotropin production in thyrotropin-secreting pituitary tumors. Thyroid. 1998;8(1):9–14.
   PubMed Web of Science ®Google Scholar
• Tagami T, Usui T, Shimatsu A, et al. Aberrant expression of thyroid hormone receptor beta isoform may cause inappropriate secretion of TSH in a TSH-secreting pituitary adenoma. J Clin Endocrinol Metab. 2011;96(6):E948–E952.
   PubMed Web of Science ®Google Scholar
• Ando S, Sarlis NJ, Oldfield EH, et al. Somatic mutation of TRβ can cause a defect in negative regulation of TSH in a TSH-secreting pituitary tumor. J Clin Endocrinol Metab. 2001;86(11):5572.
   PubMed Web of Science ®Google Scholar
• Ando S, Sarlis NJ, Krishnan J, et al. Aberrant alternative splicing of thyroid hormone receptor in a TSH-secreting pituitary tumor is a mechanism for hormone resistance. Mol Endocrinol (Baltimore, Md). 2001;15(9):1529–1538.
   PubMedGoogle Scholar
• Singh BK, Yen PM. A clinician’s guide to understanding resistance to thyroid hormone due to receptor mutations in the TRalpha and TRbeta isoforms. Clin Diabetes Endocrinol. 2017;3:8.
   PubMedGoogle Scholar
• Sapkota S, Horiguchi K, Tosaka M, et al. Whole-exome sequencing study of thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab. 2016;102(2):566-575.
   Web of Science ®Google Scholar
• Newey PJ, Nesbit MA, Rimmer AJ, et al. Whole-exome sequencing studies of nonfunctioning pituitary adenomas. J Clin Endocrinol Metab. 2013;98(4):E796–E800.
   PubMed Web of Science ®Google Scholar
• Wang Z, Ahmad A, Li Y, et al. Emerging roles of PDGF-D signaling pathway in tumor development and progression. Biochim Biophys Acta. 2010;1806(1):122–130.
   PubMed Web of Science ®Google Scholar
• Schilling SH, Hjelmeland AB, Radiloff DR, et al. NDRG4 is required for cell cycle progression and survival in glioblastoma cells. J Biol Chem. 2009;284(37):25160–25169.
   PubMed Web of Science ®Google Scholar
• Melotte V, Lentjes MH, van den Bosch SM, et al. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J Natl Cancer Inst. 2009;101(13):916–927.
   PubMed Web of Science ®Google Scholar
• Yang -J-J, Lee Y-J, Hung -H-H, et al. ZAK inhibits human lung cancer cell growth via ERK and JNK activation in an AP-1-dependent manner. Cancer Sci. 2010;101(6):1374–1381.
   PubMed Web of Science ®Google Scholar
• Liubinas SV, Munshey AS, Kaye AH. Management of recurrent craniopharyngioma. J Clin Neurosci. 2011;18(4):451–457.
   PubMed Web of Science ®Google Scholar
• Honegger J, Tatagiba M. Craniopharyngioma surgery. Pituitary. 2008;11(4):361–373.
   PubMed Web of Science ®Google Scholar
• Giangaspero F, Burger PC, Osborne DR, et al. Suprasellar papillary squamous epithelioma (“papillary craniopharyngioma”). Am J Surg Pathol. 1984;8(1):57–64.
   PubMed Web of Science ®Google Scholar
• Adamson TE, Wiestler OD, Kleihues P, et al. Correlation of clinical and pathological features in surgically treated craniopharyngiomas. J Neurosurg. 1990;73(1):12–17.
   PubMed Web of Science ®Google Scholar
• Weiner HL, Wisoff JH, Rosenberg ME, et al. Craniopharyngiomas: a clinicopathological analysis of factors predictive of recurrence and functional outcome. Neurosurgery. 1994;35(6):1001–1010.
   PubMed Web of Science ®Google Scholar
• Sekine S, Shibata T, Kokubu A, et al. Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations. Am J Pathol. 2002;161(6):1997–2001.
   PubMed Web of Science ®Google Scholar
• Cibulskis K, Lawrence MS, Carter SL, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31(3):213–219.
   PubMed Web of Science ®Google Scholar
• Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214–218.
   PubMed Web of Science ®Google Scholar
• Buslei R, Nolde M, Hofmann B, et al. Common mutations of beta-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region. Acta Neuropathol. 2005;109(6):589–597.
   PubMed Web of Science ®Google Scholar
• Clements WM, Lowy AM, Groden J. Adenomatous polyposis coli/beta-catenin interaction and downstream targets: altered gene expression in gastrointestinal tumors. Clin Colorectal Cancer. 2003;3(2):113–120.
   PubMedGoogle Scholar
• Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev. 2007;17(1):45–51.
   PubMed Web of Science ®Google Scholar
• Polakis P. Wnt signaling in cancer. Cold Spring Harb Perspect Biol. 2012;4(5):a008052-a008052.
   PubMed Web of Science ®Google Scholar
• Brastianos PK, Taylor-Weiner A, Manley PE, et al. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet. 2014;46(2):161–165.
   PubMed Web of Science ®Google Scholar
• Larkin SJ, Preda V, Karavitaki N, et al. BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma. Acta Neuropathol. 2014;127(6):927–929.
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694–1703.
   PubMed Web of Science ®Google Scholar
• Brastianos PK, Shankar GM, Gill CM, et al. Dramatic response of BRAF V600E mutant papillary craniopharyngioma to targeted therapy. J Natl Cancer Inst. 2015;108(2):1-5.
   PubMedGoogle Scholar
• Aylwin SJB, Bodi I, Beaney R. Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor. Pituitary. 2016;19(5):544–546.
   PubMed Web of Science ®Google Scholar
• Trivellin G, Daly AF, Faucz FR, et al. Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N Engl J Med. 2014;371(25):2363–2374.
   PubMed Web of Science ®Google Scholar
• Beckers A, Lodish MB, Trivellin G, et al. X-linked acrogigantism syndrome: clinical profile and therapeutic responses. Endocr Relat Cancer. 2015;22(3):353–367.
   PubMed Web of Science ®Google Scholar
• Rostomyan L, Daly AF, Petrossians P, et al. Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. Endocr Relat Cancer. 2015;22(5):745–757.
   PubMed Web of Science ®Google Scholar
• Bates B, Zhang L, Nawoschik S, et al. Characterization of Gpr101 expression and G-protein coupling selectivity. Brain Res. 2006;1087(1):1–14.
   PubMedGoogle Scholar
• Peverelli E, Mantovani G, Lania AG, et al. cAMP in the pituitary: an old messenger for multiple signals. J Mol Endocrinol. 2013;52(1):R67–R77.
   PubMed Web of Science ®Google Scholar
• Trautmann K, Thakker RV, Ellison DW, et al. Chromosomal aberrations in sporadic pituitary tumors. Int J Cancer. 2001;91(6):809–814.
   PubMed Web of Science ®Google Scholar
• Bi WL, Horowitz P, Greenwald NF, et al. Landscape of genomic alterations in pituitary adenomas. Clin Cancer Res. 2017;23(7):1841–1851.
   PubMed Web of Science ®Google Scholar
• Tanaka C, Yoshimoto K, Yang P, et al. Infrequent mutations of p27Kip1 gene and trisomy 12 in a subset of human pituitary adenomas. J Clin Endocrinol Metab. 1997;82(9):3141–3147.
   PubMed Web of Science ®Google Scholar
• Dietrich CU, Pandis N, Bjerre P, et al. Simple numerical chromosome aberrations in two pituitary adenomas. Cancer Genet Cytogenet. 1993;69(2):118–121.
   PubMedGoogle Scholar
• Rock JP, Babu VR, Drumheller T, et al. Cytogenetic findings in pituitary adenoma: results of a pilot study. Surg Neurol. 1993;40(3):224–229.
   PubMedGoogle Scholar
• Finelli P, Giardino D, Rizzi N, et al. Non-random trisomies of chromosomes 5, 8 and 12 in the prolactinoma sub-type of pituitary adenomas: conventional cytogenetics and interphase FISH study. Int J Cancer. 2000;86(3):344–350.
   PubMed Web of Science ®Google Scholar
• Larsen JB, Schroder HD, Sorensen AG, et al. Simple numerical chromosome aberrations characterize pituitary adenomas. Cancer Genet Cytogenet. 1999;114(2):144–149.
   PubMedGoogle Scholar
• Fabjani G, Tong D, Wolf A, et al. HMGA2 is associated with invasiveness but not a suitable marker for the detection of circulating tumor cells in breast cancer. Oncol Rep. 2005;14(3):737–741.
   PubMed Web of Science ®Google Scholar
• Motoyama K, Inoue H, Nakamura Y, et al. Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family. Clin Cancer Res off J Am Assoc Cancer Res. 2008;14(8):2334–2340.
   PubMed Web of Science ®Google Scholar
• Miyazawa J, Mitoro A, Kawashiri S, et al. Expression of mesenchyme-specific gene HMGA2 in squamous cell carcinomas of the oral cavity. Cancer Res. 2004;64(6):2024–2029.
   PubMed Web of Science ®Google Scholar
• Chiappetta G, Bandiera A, Berlingieri MT, et al. The expression of the high mobility group HMGI (Y) proteins correlates with the malignant phenotype of human thyroid neoplasias. Oncogene. 1995;10(7):1307–1314.
   PubMed Web of Science ®Google Scholar
• Sotillo R, Dubus P, Martin J, et al. Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors. Embo J. 2001;20(23):6637–6647.
   PubMed Web of Science ®Google Scholar
• Guo D, Han L, Shu K, et al. Down-regulation of leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) in HP75 pituitary adenoma cell line. J Huazhong Univ Sci Technolog Med Sci. 2007;27(1):91–94.
   PubMedGoogle Scholar
• Tatsi C, Pankratz N, Lane J, et al. Large genomic aberrations in corticotropinomas are associated with greater aggressiveness. J Clin Endocrinol Metab. 2019;104(5):1792–1801.
   PubMed Web of Science ®Google Scholar
• Berger SL, Kouzarides T, Shiekhattar R, et al. An operational definition of epigenetics. Genes Dev. 2009;23(7):781–783.
   PubMed Web of Science ®Google Scholar
• Fukuoka H, Takahashi Y. The role of genetic and epigenetic changes in pituitary tumorigenesis. Neurol Med Chir (Tokyo). 2014;54(12):943–957.
   Web of Science ®Google Scholar
• D’Angelo D, Palmieri D, Mussnich P, et al. Altered microRNA expression profile in human pituitary GH adenomas: down-regulation of miRNA targeting HMGA1, HMGA2, and E2F1. J Clin Endocrinol Metab. 2012;97(7):E1128–E1138.
   PubMed Web of Science ®Google Scholar
• Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99(24):15524–15529.
   PubMed Web of Science ®Google Scholar
• Pei L, Melmed S, Scheithauer B, et al. Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: evidence for a chromosome 13 tumor suppressor gene other than RB. Cancer Res. 1995;55(8):1613–1616.
   PubMed Web of Science ®Google Scholar
• Bottoni A, Piccin D, Tagliati F, et al. miR-15a and miR-16-1 down-regulation in pituitary adenomas. J Cell Physiol. 2005;204(1):280–285.
   PubMed Web of Science ®Google Scholar
• Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science. 2007;315(5818):1576–1579.
   PubMed Web of Science ®Google Scholar
• Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev. 2007;21(9):1025–1030.
   PubMed Web of Science ®Google Scholar
• Bottoni A, Zatelli MC, Ferracin M, et al. Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas. J Cell Physiol. 2007;210(2):370–377.
   PubMed Web of Science ®Google Scholar
• Palmieri D, D’Angelo D, Valentino T, et al. Downregulation of HMGA-targeting microRNAs has a critical role in human pituitary tumorigenesis. Oncogene. 2012;31(34):3857–3865.
   PubMed Web of Science ®Google Scholar
• Hauser BM, Lau A, Gupta S, et al. The epigenomics of pituitary adenoma. Front Endocrinol (Lausanne). 2019;10:290.
   PubMed Web of Science ®Google Scholar
• Mao Z-G, He D-S, Zhou J, et al. Differential expression of microRNAs in GH-secreting pituitary adenomas. Diagn Pathol. 2010;5:79.
   PubMed Web of Science ®Google Scholar
• Magali E, Anne E, Séverine E, et al. Deregulation of miR-183 and KIAA0101 in aggressive and malignant pituitary tumours. Front Med (Lausanne). 2015;2:54.
   Web of Science ®Google Scholar
• Wei Z, Zhou C, Liu M, et al. MicroRNA involvement in a metastatic non-functioning pituitary carcinoma. Pituitary. 2015;18(5):710–721.
   PubMed Web of Science ®Google Scholar
• Fang L, Li H, Wang L, et al. MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression. Oncotarget. 2014;5(10):2974–2987.
   PubMedGoogle Scholar
• Ma F, Zhang J, Zhong L, et al. Upregulated microRNA-301a in breast cancer promotes tumor metastasis by targeting PTEN and activating Wnt/beta-catenin signaling. Gene. 2014;535(2):191–197.
   PubMed Web of Science ®Google Scholar
• Kazes I, Elalamy I, Sraer JD, et al. Platelet release of trimolecular complex components MT1-MMP/TIMP2/MMP2: involvement in MMP2 activation and platelet aggregation. Blood. 2000;96(9):3064–3069.
   PubMed Web of Science ®Google Scholar
• Fu X, Calin GA. miR-122 and hepatocellular carcinoma: from molecular biology to therapeutics. Ebiomedicine. 2018;37:17–18.
   PubMed Web of Science ®Google Scholar
• Janssen HL, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013;368(18):1685–1694.
   PubMed Web of Science ®Google Scholar
• Simpson DJ, Hibberts NA, McNicol AM, et al. Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Res. 2000;60(5):1211–1216.
   PubMed Web of Science ®Google Scholar
• Bahar A, Bicknell JE, Simpson DJ, et al. Loss of expression of the growth inhibitory gene GADD45gamma, in human pituitary adenomas, is associated with CpG island methylation. Oncogene. 2004;23(4):936–944.
   PubMed Web of Science ®Google Scholar
• Ezzat S. Epigenetic control in pituitary tumors. Endocr J. 2008;55(6):951–957.
   PubMed Web of Science ®Google Scholar
• Garcia-Martinez A, Sottile J, Sanchez-Tejada L, et al. DNA methylation of tumor suppressor genes in pituitary neuroendocrine tumors. J Clin Endocrinol Metab. 2019;104(4):1272–1282.
   PubMed Web of Science ®Google Scholar
• Salomon MP, Wang X, Marzese DM, et al. The epigenomic landscape of pituitary adenomas reveals specific alterations and differentiates among acromegaly, Cushing’s disease and endocrine-inactive subtypes. Clin Cancer Res. 2018;24(17):4126–4136.
   PubMed Web of Science ®Google Scholar
• Valeri N, Gasparini P, Fabbri M, et al. Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci U S A. 2010;107(15):6982–6987.
   PubMed Web of Science ®Google Scholar
• Valeri N, Gasparini P, Braconi C, et al. MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci U S A. 2010;107(49):21098–21103.
   PubMed Web of Science ®Google Scholar
• Iseki Y, Shibutani M, Maeda K, et al. Prognostic significance of microRNA-21 expression in patients with unresectable metastatic colon cancer. Anticancer Res. 2016;36(10):5145–5151.
   PubMed Web of Science ®Google Scholar
• Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3(6):415–428.
   PubMed Web of Science ®Google Scholar
• Okano M, Xie S, Li E. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet. 1998;19(3):219–220.
   PubMed Web of Science ®Google Scholar
• Ezzat S, Cheng S, Asa SL. Epigenetics of pituitary tumors: pathogenetic and therapeutic implications. Mol Cell Endocrinol. 2018;469:70–76.
   PubMed Web of Science ®Google Scholar
• Saito Y, Kanai Y, Nakagawa T, et al. Increased protein expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the malignant potential and poor prognosis of human hepatocellular carcinomas. Int J Cancer. 2003;105(4):527–532.
   PubMed Web of Science ®Google Scholar
• Girault I, Tozlu S, Lidereau R, et al. Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin Cancer Res. 2003;9(12):4415–4422.
   PubMed Web of Science ®Google Scholar
• Etoh T, Kanai Y, Ushijima S, et al. Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. Am J Pathol. 2004;164(2):689–699.
   PubMed Web of Science ®Google Scholar
• Lin RK, Hsu HS, Chang JW, et al. Alteration of DNA methyltransferases contributes to 5ʹCpG methylation and poor prognosis in lung cancer. Lung Cancer. 2007;55(2):205–213.
   PubMed Web of Science ®Google Scholar
• Ma H-S, Wang EL, Xu W-F, et al. Overexpression of DNA (Cytosine-5)-Methyltransferase 1 (DNMT1) and DNA (Cytosine-5)-Methyltransferase 3A (DNMT3A) is associated with aggressive behavior and hypermethylation of tumor suppressor genes in human pituitary adenomas. Med Sci Monit. 2018;24:4841–4850.
   PubMed Web of Science ®Google Scholar
• Verma ME, Claude-Taupin A, Boyer-Guittaut M, et al. Use of epigenetic modulators as a powerful adjuvant for breast cancer therapies. (Ed.^(Eds)). New York, NY: Humana Press; 2014. p. 487.
   Google Scholar
• Daher-Reyes GS, Merchan BM, Yee KWL. Guadecitabine (SGI-110): an investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Expert Opin Investig Drugs. 2019;28:1–15.
   Web of Science ®Google Scholar
• Garcia-Manero G, Roboz G, Walsh K, et al. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. Lancet Haematol. 2019;6(6):e317–e327.
   PubMed Web of Science ®Google Scholar
• McCormack AI, Wass JA, Grossman AB. Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. Eur J Clin Invest. 2011;41(10):1133–1148.
   PubMed Web of Science ®Google Scholar
• Wang W, Fu L, Li S, et al. Histone deacetylase 11 suppresses p53 expression in pituitary tumor cells. Cell Biol Int. 2017;41(12):1290–1295.
   PubMed Web of Science ®Google Scholar
• Grande IPP, Amorim P, Freire A, et al. Differential gene expression of sirtuins between somatotropinomas and nonfunctioning pituitary adenomas. Pituitary. 2018;21(4):355–361.
   PubMed Web of Science ®Google Scholar
• Ezzat S, Yu S, Asa SL. The zinc finger Ikaros transcription factor regulates pituitary growth hormone and prolactin gene expression through distinct effects on chromatin accessibility. Mol Endocrinol. 2005;19(4):1004–1011.
   PubMedGoogle Scholar
• Ezzat S, Mader R, Yu S, et al. Ikaros integrates endocrine and immune system development. J Clin Invest. 2005;115(4):1021–1029.
   PubMed Web of Science ®Google Scholar
• Yu S, Asa SL, Ezzat S. Fibroblast growth factor receptor 4 is a target for the zinc-finger transcription factor Ikaros in the pituitary. Mol Endocrinol. 2002;16(5):1069–1078.
   PubMedGoogle Scholar
• Ezzat S, Zhu X, Loeper S, et al. Tumor-derived Ikaros 6 acetylates the Bcl-XL promoter to up-regulate a survival signal in pituitary cells. Mol Endocrinol. 2006;20(11):2976–2986.
   PubMedGoogle Scholar
• Ezzat S, Mader R, Fischer S, et al. An essential role for the hematopoietic transcription factor Ikaros in hypothalamic-pituitary-mediated somatic growth. Proc Natl Acad Sci U S A. 2006;103(7):2214–2219.
   PubMed Web of Science ®Google Scholar
• Ahuja N, Sharma AR, Baylin SB. Epigenetic therapeutics: a new weapon in the war against cancer. Annu Rev Med. 2016;67:73–89.
   PubMed Web of Science ®Google Scholar
• West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. (Ed.^(Eds)). Am Soc Clin Invest U S. 2014;124(1):30-39.
   Google Scholar
• Juergens RA, Wrangle J, Vendetti FP, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 2011;1(7):598–607.
   PubMed Web of Science ®Google Scholar
• Maslak P, Chanel S, Camacho LH, et al. Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. Leukemia. 2006;20(2):212–217.
   PubMed Web of Science ®Google Scholar